Lista de obras -

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

artículo científico publicado en 2002

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

artículo científico publicado en 2007

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer

artículo científico publicado en 2002

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

artículo científico publicado en 2006

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

scientific article published on 19 May 2020

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

artículo científico publicado en 2009

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. ⬇️

artículo científico publicado en 2012

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors

artículo científico publicado en 2002

Coprescription of tamoxifen and medications that inhibit CYP2D6.

artículo científico publicado en 2010

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

scientific article published on September 2008

Endocrine therapy in 2009: consideration of the tumor and the host.

artículo científico publicado en 2009

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

artículo científico publicado en 2011

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

artículo científico publicado en 2015

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

artículo científico publicado en 2017

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

scientific article published on 01 September 2007

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

artículo científico publicado en 2014

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

artículo científico publicado en 2008

Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.

artículo científico publicado en 2007

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

artículo científico publicado en 2005

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

artículo científico publicado en 2005

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors

artículo científico publicado en 2003

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

artículo científico publicado en 2005

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

artículo científico publicado en 2005

Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model

artículo científico publicado en 2004

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

artículo científico publicado en 2011

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention ⬇️

artículo científico publicado el 13 de junio de 2013

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

artículo científico publicado en 2006

Lista de obras de

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. ⬇️

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors

Coprescription of tamoxifen and medications that inhibit CYP2D6.

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

Endocrine therapy in 2009: consideration of the tumor and the host.

Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

Identification and characterization of genetic variation in the folylpolyglutamate synthase gene

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention ⬇️

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen